• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Jim Graham of Prime Therapeutics Discusses a Digital Transformation Management System in Healthcare


In this week's episode, MHE Editor Briana Contreras and Managing Editor Peter Wehrwein met with CIO of Prime Therapeutics, Jim Graham to discuss the process of an organization’s digital transformation from a traditional Pharmacy Benefit Manager to a complete data-driven drug management system. Graham addressed the risks an organization may come across to successfully transition to this system, but also mentioned the benefits to come.

To listen to more episodes featured on Tuning Into The C-Suite, visit us on Spotify, Apple Podcasts and iHeartRadio.

Topics in this Discussion

  • Most important aspects of digital transformation at Prime and what is unique about them? 01:10
  • Collaboration with Express Script in these efforts? Is Prime free to go its own way with these efforts or are you coordinating closely with Express Scripts? 05:30
  • PBMs have gotten a reputation as middlemen who extract revenue from the drug supply chain without adding a commensurate amount of value. Will your digital transformation efforts help address the industry’s reputation problems? 06:47
  • How might your digital transformation efforts affect drug prices – and if not prices, perhaps drug expenditures? 11:33
  • Digital efforts also raise issues about data privacy and cybersecurity. What is Prime doing to protect data privacy? 14:50
  • There are many entities in healthcare who want to leverage data from and about patients. Are you concerned about too many entities focusing on care coordination? 16:45
  • Personal experience that inspired data sharing. 19:15
Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.